Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 164 articles:
HTML format



Single Articles


    March 2024
  1. ANANTHAKRISHNAN AN
    Inflammatory bowel diseases: are we ready to recommend a preventive diet for infants?
    Gut. 2024;73:559-560.
    PubMed    


  2. SCHULZ-KUHNT A, Ruhle K, Javidmehr A, Dobronti M, et al
    ATP citrate lyase (ACLY)-dependent immunometabolism in mucosal T cells drives experimental colitis in vivo.
    Gut. 2024;73:601-612.
    PubMed     Abstract available


    February 2024
  3. ABDELRAHIM M, Siggens K, Iwadate Y, Maeda N, et al
    New AI model for neoplasia detection and characterisation in inflammatory bowel disease.
    Gut. 2024 Feb 23:gutjnl-2023-330718. doi: 10.1136/gutjnl-2023-330718.
    PubMed    


  4. ZHANG L, Agrawal M, Ng SC, Jess T, et al
    Early-life exposures and the microbiome: implications for IBD prevention.
    Gut. 2024;73:541-549.
    PubMed     Abstract available


  5. ADOLPH TE
    It is in the matrix: a molecular clue to fibro-stenotic Crohn's disease.
    Gut. 2024 Feb 20:gutjnl-2024-332016. doi: 10.1136/gutjnl-2024-332016.
    PubMed    


  6. AN H, Zhong M, Gan H
    Proton pump inhibitors and the risk of inflammatory bowel disease: a Mendelian randomisation study.
    Gut. 2024 Feb 15:gutjnl-2024-331904. doi: 10.1136/gutjnl-2024-331904.
    PubMed    


    January 2024
  7. GUO A, Ludvigsson J, Brantsaeter AL, Klingberg S, et al
    Early-life diet and risk of inflammatory bowel disease: a pooled study in two Scandinavian birth cohorts.
    Gut. 2024 Jan 30:gutjnl-2023-330971. doi: 10.1136/gutjnl-2023-330971.
    PubMed     Abstract available


  8. SUN J, Yao J, Olen O, Halfvarson J, et al
    Familial coaggregation of inflammatory bowel disease with cardiovascular disease: a nationwide multigenerational cohort study.
    Gut. 2024 Jan 6:gutjnl-2023-331632. doi: 10.1136/gutjnl-2023-331632.
    PubMed    


  9. CHIRIAC MT, Hracsko Z, Gunther C, Gonzalez-Acera M, et al
    IL-20 controls resolution of experimental colitis by regulating epithelial IFN/STAT2 signalling.
    Gut. 2024;73:282-297.
    PubMed     Abstract available


    December 2023
  10. ERIKSEN C, Danneskiold-Samsoe NB, Moll JM, Myers PN, et al
    Specific gut pathobionts escape antibody coating and are enriched during flares in patients with severe Crohn's disease.
    Gut. 2023 Dec 16:gutjnl-2023-330677. doi: 10.1136/gutjnl-2023-330677.
    PubMed     Abstract available


  11. MINERVINA AA, Pogorelyy MV, Paysen S, Luening U, et al
    Crohn's-associated invariant T cells (CAITs) recognise small sulfonate molecules on CD1d.
    Gut. 2023;73:205-206.
    PubMed    


    November 2023
  12. TUN HM, Peng Y, Massimino L, Sin ZY, et al
    Gut virome in inflammatory bowel disease and beyond.
    Gut. 2023 Nov 10:gutjnl-2023-330001. doi: 10.1136/gutjnl-2023-330001.
    PubMed     Abstract available


  13. ULLRICH KA, Derdau J, Baltes C, Battistella A, et al
    IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells.
    Gut. 2023;72:2081-2094.
    PubMed     Abstract available


    October 2023
  14. MUKHOPADHYA I
    Is HBx protein the X factor in the pathogenesis of IBD?
    Gut. 2023;72:1808-1809.
    PubMed    


    September 2023
  15. MA Y, Zhang X, Xuan B, Li D, et al
    Disruption of CerS6-mediated sphingolipid metabolism by FTO deficiency aggravates ulcerative colitis.
    Gut. 2023 Sep 21:gutjnl-2023-330009. doi: 10.1136/gutjnl-2023-330009.
    PubMed     Abstract available


  16. JIANG L, Li JC, Shen L, Tang BS, et al
    Association between inflammatory bowel disease and Alzheimer's disease: multivariable and bidirectional Mendelian randomisation analyses.
    Gut. 2023;72:1797-1799.
    PubMed    


  17. CHURCHHOUSE AM, Moffat VE, Selinger CP, Lamb CA, et al
    British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance.
    Gut. 2023;72:1631-1634.
    PubMed    


    August 2023
  18. SCHWARZLER J, Zollner A, Dolejsi T, Mayr L, et al
    Inflammatory bowel disease in STAT1 gain-of-function immunodeficiency treated with precision medicine.
    Gut. 2023 Aug 24:gutjnl-2023-330588. doi: 10.1136/gutjnl-2023-330588.
    PubMed    


  19. CHETWOOD JD, Paramsothy S, Haifer C, Leong RW, et al
    Key metabolomic alterations are associated with ulcerative colitis disease state and activity: a validation analysis.
    Gut. 2023 Aug 17:gutjnl-2023-330196. doi: 10.1136/gutjnl-2023-330196.
    PubMed    


  20. WAUTERS L, Tito RY, Ceulemans M, Outtier A, et al
    Microbiome variance of the small bowel in Crohn's disease.
    Gut. 2023;72:1626-1628.
    PubMed    


    July 2023
  21. BECKER C, Adolph TE
    Disentangling tryptophan metabolism in inflammatory bowel diseases.
    Gut. 2023;72:1235-1236.
    PubMed    


  22. LEE JC
    Going deeper: molecular inflammatory scores in IBD.
    Gut. 2023;72:1233-1234.
    PubMed    


  23. MICHAUDEL C, Danne C, Agus A, Magniez A, et al
    Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases.
    Gut. 2023;72:1296-1307.
    PubMed     Abstract available


  24. ARGMANN C, Hou R, Ungaro RC, Irizar H, et al
    Biopsy and blood-based molecular biomarker of inflammation in IBD.
    Gut. 2023;72:1271-1287.
    PubMed     Abstract available


    June 2023
  25. DE BOER NKH, Simsek M, Meijer B, Neurath MF, et al
    Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease.
    Gut. 2023 Jun 28:gutjnl-2023-329679. doi: 10.1136/gutjnl-2023-329679.
    PubMed     Abstract available


  26. LOPETUSO LR, Deleu S, Godny L, Petito V, et al
    The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease.
    Gut. 2023 Jun 20:gutjnl-2023-329948. doi: 10.1136/gutjnl-2023-329948.
    PubMed     Abstract available


  27. SCHWARZFISCHER M, Niechcial A, Handler K, Morsy Y, et al
    TiO(2) nanoparticles abrogate the protective effect of the Crohn's disease-associated variation within the PTPN22 gene locus.
    Gut. 2023;72:1101-1114.
    PubMed     Abstract available


  28. MILLET V, Gensollen T, Maltese M, Serrero M, et al
    Harnessing the Vnn1 pantetheinase pathway boosts short chain fatty acids production and mucosal protection in colitis.
    Gut. 2023;72:1115-1128.
    PubMed     Abstract available


  29. DANNE C, Michaudel C, Skerniskyte J, Planchais J, et al
    CARD9 in neutrophils protects from colitis and controls mitochondrial metabolism and cell survival.
    Gut. 2023;72:1081-1092.
    PubMed     Abstract available


    May 2023
  30. PAL P, Ramchandani M, Banerjee R, Viswakarma P, et al
    Technical performance and diagnostic yield of motorised spiral enteroscopy compared with single-balloon enteroscopy in suspected Crohn's disease: a randomised controlled, open-label study (the MOTOR-CD trial).
    Gut. 2023 May 17:gutjnl-2023-329885. doi: 10.1136/gutjnl-2023-329885.
    PubMed     Abstract available


  31. LU H, Zhang C, Wu W, Chen H, et al
    MCPIP1 restrains mucosal inflammation by orchestrating the intestinal monocyte to macrophage maturation via an ATF3-AP1S2 axis.
    Gut. 2023;72:882-895.
    PubMed     Abstract available


  32. ZUO L, Kuo WT, Cao F, Chanez-Paredes SD, et al
    Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn's disease.
    Gut. 2023;72:870-881.
    PubMed     Abstract available


    April 2023
  33. GHATE A, Uhlig HH
    Defective microbial sensing and clearance in perianal Crohn's disease: a role for complement factor B.
    Gut. 2023 Apr 25:gutjnl-2023-329801. doi: 10.1136/gutjnl-2023-329801.
    PubMed    


  34. AKHLAGHPOUR M, Haritunians T, More SK, Thomas LS, et al
    Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis.
    Gut. 2023 Apr 20:gutjnl-2023-329689. doi: 10.1136/gutjnl-2023-329689.
    PubMed     Abstract available


  35. ZHAO J, Chen J, Sun Y, Yuan S, et al
    Defining gene-lifestyle interactions in inflammatory bowel disease: progress towards understanding disease pathogenesis.
    Gut. 2023 Apr 4:gutjnl-2023-329875. doi: 10.1136/gutjnl-2023-329875.
    PubMed    


  36. YE BD
    Proton pump inhibitors and the risk of inflammatory bowel disease: cause, protopathic bias or others?
    Gut. 2023 Apr 4:gutjnl-2023-329506. doi: 10.1136/gutjnl-2023-329506.
    PubMed    


  37. HSU NY, Nayar S, Gettler K, Talware S, et al
    NOX1 is essential for TNFalpha-induced intestinal epithelial ROS secretion and inhibits M cell signatures.
    Gut. 2023;72:654-662.
    PubMed     Abstract available


  38. AGRAWAL M, Poulsen G, Colombel JF, Allin KH, et al
    Maternal antibiotic exposure during pregnancy and risk of IBD in offspring: a population-based cohort study.
    Gut. 2023;72:804-805.
    PubMed    


    March 2023
  39. FAYE AS, Jess T
    Antibiotic use and inflammatory bowel disease: number needed to harm? Authors' reply.
    Gut. 2023 Mar 27:gutjnl-2023-329851. doi: 10.1136/gutjnl-2023-329851.
    PubMed    


  40. VICH VILA A, Hu S, Andreu-Sanchez S, Collij V, et al
    Faecal metabolome and its determinants in inflammatory bowel disease.
    Gut. 2023 Mar 23:gutjnl-2022-328048. doi: 10.1136/gutjnl-2022-328048.
    PubMed     Abstract available


  41. LAUBE R, Selinger CP, Seow CH, Christensen B, et al
    Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding.
    Gut. 2023 Mar 21:gutjnl-2022-329304. doi: 10.1136/gutjnl-2022-329304.
    PubMed     Abstract available


  42. ZHANG E, Nguyen THO, Allen LF, Kedzierski L, et al
    Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments.
    Gut. 2023 Mar 6:gutjnl-2022-329136. doi: 10.1136/gutjnl-2022-329136.
    PubMed    


  43. ADAMS A, Gupta V, Mohsen W, Chapman TP, et al
    Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response.
    Gut. 2023;72:433-442.
    PubMed     Abstract available


  44. PIERRE N, Huynh-Thu VA, Marichal T, Allez M, et al
    Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab: when the remission state hides different types of residual disease activity.
    Gut. 2023;72:443-450.
    PubMed     Abstract available


    February 2023
  45. LUDVIGSSON JF
    Antibiotic use and inflammatory bowel disease: number needed to harm?
    Gut. 2023 Feb 21:gutjnl-2023-329575. doi: 10.1136/gutjnl-2023-329575.
    PubMed    


  46. LEIBOVITZH H, Lee SH, Raygoza Garay JA, Espin-Garcia O, et al
    Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn's disease highlight earliest events of pathogenesis.
    Gut. 2023 Feb 14:gutjnl-2022-328421. doi: 10.1136/gutjnl-2022-328421.
    PubMed     Abstract available


  47. MASSIMINO L, Palmieri O, Facoetti A, Fuggetta D, et al
    Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo.
    Gut. 2023 Feb 14:gutjnl-2022-328375. doi: 10.1136/gutjnl-2022-328375.
    PubMed     Abstract available


  48. WAGNER F, Mansfield JC, Lekkerkerker AN, Wang Y, et al
    Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis.
    Gut. 2023 Feb 2:gutjnl-2022-328387. doi: 10.1136/gutjnl-2022-328387.
    PubMed     Abstract available


  49. BARBERIO B, Gracie DJ, Black CJ, Ford AC, et al
    Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis.
    Gut. 2023;72:264-274.
    PubMed     Abstract available


  50. KENNEDY NA, Janjua M, Chanchlani N, Lin S, et al
    Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.
    Gut. 2023;72:295-305.
    PubMed     Abstract available


  51. LEES CW, Ahmad T, Lamb CA, Powell N, et al
    Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity.
    Gut. 2023;72:410-412.
    PubMed    


  52. HAAG LM, Siegmund B
    Epithelial RAC1 niches in IBD: from barrier integrity to cytoskeletal plasticity.
    Gut. 2023;72:219-220.
    PubMed    


  53. MARTINEZ-SANCHEZ LDC, Ngo PA, Pradhan R, Becker LS, et al
    Epithelial RAC1-dependent cytoskeleton dynamics controls cell mechanics, cell shedding and barrier integrity in intestinal inflammation.
    Gut. 2023;72:275-294.
    PubMed     Abstract available


    January 2023
  54. ABRAHAMI D, Pradhan R, Yin H, Yanofsky R, et al
    Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study.
    Gut. 2023 Jan 30:gutjnl-2022-328866. doi: 10.1136/gutjnl-2022-328866.
    PubMed     Abstract available


  55. FAYE AS, Allin KH, Iversen AT, Agrawal M, et al
    Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study.
    Gut. 2023 Jan 9:gutjnl-2022-327845. doi: 10.1136/gutjnl-2022-327845.
    PubMed     Abstract available


  56. LIU Q, Cammarota G, Ianiro G
    Evaluating microbial determinants of donor efficacy to translate faecal microbiota transplantation from research to clinical practice.
    Gut. 2023;72:5-7.
    PubMed    


  57. ELSON CO
    Adherent invasive Escherichia coli in Crohn's disease: guilt by association?
    Gut. 2023;72:2-3.
    PubMed    


  58. BUISSON A, Sokol H, Hammoudi N, Nancey S, et al
    Role of adherent and invasive Escherichia coli in Crohn's disease: lessons from the postoperative recurrence model.
    Gut. 2023;72:39-48.
    PubMed     Abstract available


    December 2022
  59. LOPES EW, Chan SSM, Song M, Ludvigsson JF, et al
    Lifestyle factors for the prevention of inflammatory bowel disease.
    Gut. 2022 Dec 6:gutjnl-2022-328174. doi: 10.1136/gutjnl-2022-328174.
    PubMed     Abstract available


  60. ADOLPH TE, Zhang J
    Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts.
    Gut. 2022;71:2574-2586.
    PubMed     Abstract available


  61. SALAS A
    What good can neutrophils do in UC?
    Gut. 2022;71:2375-2376.
    PubMed    


  62. LETT MJ, Mehta H, Keogh A, Jaeger T, et al
    Stimulatory MAIT cell antigens reach the circulation and are efficiently metabolised and presented by human liver cells.
    Gut. 2022;71:2526-2538.
    PubMed     Abstract available


    November 2022
  63. MANSOOR E, Martin SA, Perez A, Nguyen VQ, et al
    Reply to Newman et al 'Response to epidemiology of inflammatory bowel disease in men with high-risk homosexual activity'.
    Gut. 2022 Nov 2. pii: gutjnl-2022-328883. doi: 10.1136/gutjnl-2022-328883.
    PubMed    


  64. SCHIEPATTI A, Sanders DS, Baiardi P, Caio G, et al
    Nomenclature and diagnosis of seronegative coeliac disease and chronic non-coeliac enteropathies in adults: the Paris consensus.
    Gut. 2022;71:2218-2225.
    PubMed     Abstract available


  65. ROSATI E, Rios Martini G, Pogorelyy MV, Minervina AA, et al
    A novel unconventional T cell population enriched in Crohn's disease.
    Gut. 2022;71:2194-2204.
    PubMed     Abstract available


  66. HUO X, Li D, Wu F, Li S, et al
    Cultivated human intestinal fungus Candida metapsilosis M2006B attenuates colitis by secreting acyclic sesquiterpenoids as FXR agonists.
    Gut. 2022;71:2205-2217.
    PubMed     Abstract available


  67. WARD D, Andersson M, Nyboe Andersen N, Allin KH, et al
    Risk of acute arterial events associated with treatment of inflammatory bowel diseases: a nationwide Danish cohort study.
    Gut. 2022;71:2373-2374.
    PubMed    


    October 2022
  68. NEWMAN KL, Jencks K, Chedid V, Paul S, et al
    Response to Mansoor et al: 'epidemiology of inflammatory bowel disease in men with high-risk homosexual activity'.
    Gut. 2022 Oct 13. pii: gutjnl-2022-328802. doi: 10.1136/gutjnl-2022-328802.
    PubMed    


    September 2022
  69. SUDHAKAR P, Wellens J, Verstockt B, Ferrante M, et al
    Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?
    Gut. 2022 Sep 28. pii: gutjnl-2022-328221. doi: 10.1136/gutjnl-2022-328221.
    PubMed     Abstract available


  70. ZOLLER H, Wolf M, Blumenstein I, Primas C, et al
    Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
    Gut. 2022 Sep 9. pii: gutjnl-2022-327897. doi: 10.1136/gutjnl-2022-327897.
    PubMed     Abstract available


  71. KIRCHGESNER J, Desai RJ, Schneeweiss MC, Beaugerie L, et al
    Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease.
    Gut. 2022;71:1781-1789.
    PubMed     Abstract available


  72. CANNATELLI R, Ferretti F, Carmagnola S, Bergna IMB, et al
    Risk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD.
    Gut. 2022;71:1926-1928.
    PubMed    


  73. FAIRBRASS KM, Lovatt J, Barberio B, Yuan Y, et al
    Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis.
    Gut. 2022;71:1773-1780.
    PubMed     Abstract available


  74. MANSOOR E, Martin SA, Perez A, Nguyen VQ, et al
    Epidemiology of inflammatory bowel disease in men with high-risk homosexual activity.
    Gut. 2022 Sep 1. pii: gutjnl-2022-328218. doi: 10.1136/gutjnl-2022-328218.
    PubMed    


    August 2022
  75. KEDIA S, Virmani S, K Vuyyuru S, Kumar P, et al
    Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial.
    Gut. 2022 Aug 16. pii: gutjnl-2022-327811. doi: 10.1136/gutjnl-2022-327811.
    PubMed     Abstract available


  76. RIMOLA J, Torres J, Kumar S, Taylor SA, et al
    Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease.
    Gut. 2022 Aug 4. pii: gutjnl-2021-326562. doi: 10.1136/gutjnl-2021-326562.
    PubMed     Abstract available


  77. GUO X, Chong L, Zhang X, Li R, et al
    Letter to the editor: Genetically determined IBD is associated with decreased risk of Alzheimer's disease: a Mendelian randomisation study.
    Gut. 2022;71:1688-1689.
    PubMed    


  78. ADOLPH TE, Siegmund B
    Deciphering the vedolizumab dosing conundrum in IBD: when less is more.
    Gut. 2022;71:1455-1456.
    PubMed    


  79. BECKER E, Dedden M, Gall C, Wiendl M, et al
    Residual homing of alpha4beta7-expressing beta1(+)PI16(+) regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab.
    Gut. 2022;71:1551-1566.
    PubMed     Abstract available


    July 2022
  80. IACUCCI M, Parigi TL, Bazarova A, Ghosh S, et al
    Response to: Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificia
    Gut. 2022 Jul 27. pii: gutjnl-2022-327980. doi: 10.1136/gutjnl-2022-327980.
    PubMed    


  81. XIONG S, Whitehurst CE, Li L, Heo GS, et al
    Reverse translation approach generates a signature of penetrating fibrosis in Crohn's disease that is associated with anti-TNF response.
    Gut. 2022;71:1289-1301.
    PubMed     Abstract available


    June 2022
  82. DANESE S, Solitano V, Jairath V, Peyrin-Biroulet L, et al
    The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment).
    Gut. 2022 Jun 14. pii: gutjnl-2022-327025. doi: 10.1136/gutjnl-2022-327025.
    PubMed    


  83. WONG ECL, Dulai PS, Narula N
    Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligenc
    Gut. 2022 Jun 7. pii: gutjnl-2022-327661. doi: 10.1136/gutjnl-2022-327661.
    PubMed    


  84. STIDHAM RW, Vickers A, Singh K, Waljee AK, et al
    From clinical trials to clinical practice: how should we design and evaluate prediction models in the care of IBD?
    Gut. 2022;71:1046-1047.
    PubMed    


  85. KAPLAN GG, Ma C, Charlton C, Kanji JN, et al
    Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study.
    Gut. 2022;71:1229-1231.
    PubMed    


  86. NARULA N, Wong ECL, Colombel JF, Sandborn WJ, et al
    Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD).
    Gut. 2022;71:1078-1087.
    PubMed     Abstract available


    May 2022
  87. QUAN J, Ma C, Panaccione R, Hracs L, et al
    Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease.
    Gut. 2022 May 23. pii: gutjnl-2022-327440. doi: 10.1136/gutjnl-2022-327440.
    PubMed    


    April 2022
  88. LIN S, Lau LH, Chanchlani N, Kennedy NA, et al
    Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.
    Gut. 2022 Apr 27. pii: gutjnl-2021-326784. doi: 10.1136/gutjnl-2021-326784.
    PubMed     Abstract available


  89. VOSKENS C, Stoica D, Rosenberg M, Vitali F, et al
    Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis.
    Gut. 2022 Apr 15. pii: gutjnl-2022-327075. doi: 10.1136/gutjnl-2022-327075.
    PubMed     Abstract available


  90. JESS T, Vestergaard MV, Iversen AT, Allin KH, et al
    Undiagnosed inflammatory bowel disease among individuals undergoing colorectal cancer screening: a nationwide Danish cohort study 2014-2018.
    Gut. 2022 Apr 12. pii: gutjnl-2022-327296. doi: 10.1136/gutjnl-2022-327296.
    PubMed    


  91. RAINE T, Pavey H, Qian W, Moran GW, et al
    Establishment of a validated central reading system for ileocolonoscopy in an academic setting.
    Gut. 2022;71:661-664.
    PubMed    


  92. JIMENEZ-VARGAS NN, Yu Y, Jensen DD, Bok DD, et al
    Agonist that activates the micro-opioid receptor in acidified microenvironments inhibits colitis pain without side effects.
    Gut. 2022;71:695-704.
    PubMed     Abstract available


    March 2022
  93. GORDON IO, Bettenworth D, Bokemeyer A, Srivastava A, et al
    International consensus to standardise histopathological scoring for small bowel strictures in Crohn's disease.
    Gut. 2022;71:479-486.
    PubMed     Abstract available


  94. PAGANO E, Elias JE, Schneditz G, Saveljeva S, et al
    Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment.
    Gut. 2022;71:509-520.
    PubMed     Abstract available


    February 2022
  95. GUI X, Bazarova A, Del Amor R, Vieth M, et al
    PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system.
    Gut. 2022 Feb 16. pii: gutjnl-2021-326376. doi: 10.1136/gutjnl-2021-326376.
    PubMed     Abstract available


  96. LI X, Tong X, Wong ICK, Peng K, et al
    Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study.
    Gut. 2022 Feb 8. pii: gutjnl-2021-326860. doi: 10.1136/gutjnl-2021-326860.
    PubMed    


  97. MA C, Khanna R, Guizzetti L, Zou G, et al
    Methods for handling missing segments in Crohn's disease clinical trials: analysis from the EXTEND trial.
    Gut. 2022;71:447-448.
    PubMed    


  98. LIU Z, Liu X, Liang J, Shi Y, et al
    Unusual cause of bloody stool with earache and saddle-nose deformity.
    Gut. 2022;71:264-356.
    PubMed    


    January 2022
  99. SPALINGER MR, Shawki A, Chatterjee P, Canale V, et al
    Autoimmune susceptibility gene PTPN2 is required for clearance of adherent-invasive Escherichia coli by integrating bacterial uptake and lysosomal defence.
    Gut. 2022;71:89-99.
    PubMed     Abstract available


  100. MAO R, Doyon G, Gordon IO, Li J, et al
    Activated intestinal muscle cells promote preadipocyte migration: a novel mechanism for creeping fat formation in Crohn's disease.
    Gut. 2022;71:55-67.
    PubMed     Abstract available


  101. JONGSMA MME, Aardoom MA, Cozijnsen MA, van Pieterson M, et al
    First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
    Gut. 2022;71:34-42.
    PubMed     Abstract available


    December 2021
  102. BURR NE, Gracie DJ, Black CJ, Ford AC, et al
    Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis.
    Gut. 2021 Dec 22. pii: gutjnl-2021-326390. doi: 10.1136/gutjnl-2021-326390.
    PubMed     Abstract available


  103. WELLENS J, Edmans M, Obolski U, McGregor CG, et al
    Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.
    Gut. 2021 Dec 15. pii: gutjnl-2021-326312. doi: 10.1136/gutjnl-2021-326312.
    PubMed    


  104. LEPPKES M, Lindemann A, Gosswein S, Paulus S, et al
    Neutrophils prevent rectal bleeding in ulcerative colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis.
    Gut. 2021 Dec 3. pii: gutjnl-2021-324725. doi: 10.1136/gutjnl-2021-324725.
    PubMed     Abstract available


  105. MCGREGOR CG, Adams A, Sadler R, Arancibia-Carcamo CV, et al
    Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.
    Gut. 2021;70:2398-2400.
    PubMed    


  106. WELLENS J, Sabino J, Vermeire S
    PPIs and anti-TNF in patients with IBD: a forbidden combination?
    Gut. 2021;70:2397-2398.
    PubMed    


  107. NA YR, Jung D, Stakenborg M, Jang H, et al
    Prostaglandin E2 receptor PTGER4-expressing macrophages promote intestinal epithelial barrier regeneration upon inflammation.
    Gut. 2021;70:2249-2260.
    PubMed     Abstract available


    November 2021
  108. SHIRE ZJ, Reicherz F, Lawrence S, Sudan H, et al
    Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy.
    Gut. 2021 Nov 23. pii: gutjnl-2021-326196. doi: 10.1136/gutjnl-2021-326196.
    PubMed    


  109. CROUWEL F, Buiter HJC, de Boer NKH
    There is still a place for optimised thiopurine therapy in IBD.
    Gut. 2021;70:2207.
    PubMed    


    October 2021
  110. ODUFALU FD, Long M, Lin K, Mahadevan U, et al
    Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry.
    Gut. 2021 Oct 22. pii: gutjnl-2021-325317. doi: 10.1136/gutjnl-2021-325317.
    PubMed     Abstract available


  111. ATTAUABI M, Seidelin J, Burisch J
    Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?
    Gut. 2021;70:2020-2022.
    PubMed    


  112. KENNEDY NA, Lin S, Goodhand JR, Chanchlani N, et al
    Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
    Gut. 2021;70:1884-1893.
    PubMed     Abstract available


  113. JUKIC A, Bakiri L, Wagner EF, Tilg H, et al
    Calprotectin: from biomarker to biological function.
    Gut. 2021;70:1978-1988.
    PubMed     Abstract available


    September 2021
  114. KHAN N, Mahmud N, Trivedi C, Reinisch W, et al
    Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System.
    Gut. 2021;70:1657-1664.
    PubMed     Abstract available


  115. ADEGBOLA SO, Dibley L, Sahnan K, Wade T, et al
    Development and initial psychometric validation of a patient-reported outcome measure for Crohn's perianal fistula: the Crohn's Anal Fistula Quality of Life (CAF-QoL) scale.
    Gut. 2021;70:1649-1656.
    PubMed     Abstract available


  116. KANDIAH K, Subramaniam S, Thayalasekaran S, Chedgy FJ, et al
    Multicentre randomised controlled trial on virtual chromoendoscopy in the detection of neoplasia during colitis surveillance high-definition colonoscopy (the VIRTUOSO trial).
    Gut. 2021;70:1684-1690.
    PubMed     Abstract available


    August 2021
  117. GORELIK Y, Freilich S, Gerassy-Vainberg S, Pressman S, et al
    Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFalpha therapy in inflammatory bowel disease patients: a report from the epi-IIRN.
    Gut. 2021 Aug 3. pii: gutjnl-2021-325185. doi: 10.1136/gutjnl-2021-325185.
    PubMed     Abstract available


    July 2021
  118. VERSTOCKT B, Boets L, Sabino J, Vermeire S, et al
    Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease.
    Gut. 2021;70:1416-1418.
    PubMed    


  119. CARON B, Sandborn WJ, Schreiber S, Panaccione R, et al
    Drug development for ulcerative proctitis: current concepts.
    Gut. 2021;70:1203-1209.
    PubMed    


    June 2021
  120. HANSEN R, Meade S, Beattie RM, Auth MK, et al
    Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel.
    Gut. 2021;70:1044-1052.
    PubMed     Abstract available


  121. AGRAWAL M, Corn G, Shrestha S, Nielsen NM, et al
    Inflammatory bowel diseases among first-generation and second-generation immigrants in Denmark: a population-based cohort study.
    Gut. 2021;70:1037-1043.
    PubMed     Abstract available


    May 2021
  122. CURTIUS K, Kabir M, Al Bakir I, Choi CHR, et al
    Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool.
    Gut. 2021 May 14. pii: gutjnl-2020-323546. doi: 10.1136/gutjnl-2020-323546.
    PubMed     Abstract available


  123. KENNEDY NA, Goodhand JR, Bewshea C, Nice R, et al
    Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
    Gut. 2021;70:865-875.
    PubMed     Abstract available


  124. AXELRAD JE, Olen O, Sachs MC, Erichsen R, et al
    Reply: Survival in Crohn's disease-associated small bowel adenocarcinoma.
    Gut. 2021;70:998.
    PubMed    


  125. GIUFFRIDA P, Vanoli A, Di Sabatino A
    Survival in Crohn's disease-associated small bowel adenocarcinoma.
    Gut. 2021;70:997-998.
    PubMed    


    April 2021
  126. BOLTE LA, Vich Vila A, Imhann F, Collij V, et al
    Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome.
    Gut. 2021 Apr 2. pii: gutjnl-2020-322670. doi: 10.1136/gutjnl-2020-322670.
    PubMed     Abstract available



  127. Correction: British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
    Gut. 2021;70:1.
    PubMed    


  128. LEES CW, Irving PM, Beaugerie L
    COVID-19 and IBD drugs: should we change anything at the moment?
    Gut. 2021;70:632-634.
    PubMed    


  129. SIEGEL CA, Melmed GY, McGovern DP, Rai V, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.
    Gut. 2021;70:635-640.
    PubMed    


  130. UNGARO RC, Brenner EJ, Gearry RB, Kaplan GG, et al
    Effect of IBD medications on COVID-19 outcomes: results from an international registry.
    Gut. 2021;70:725-732.
    PubMed     Abstract available


  131. ZHAO R, Wan QY, Wu Y, Wang Y, et al
    Crohn's disease instead of UC might increase the risk of small bowel cancer.
    Gut. 2021;70:809-810.
    PubMed    


  132. GREUTER T, Rieder F, Kucharzik T, Peyrin-Biroulet L, et al
    Emerging treatment options for extraintestinal manifestations in IBD.
    Gut. 2021;70:796-802.
    PubMed     Abstract available


    March 2021
  133. ASHTON JJ, Ennis S, Beattie RM
    Infliximab at diagnosis: moving towards personalisation in paediatric inflammatory bowel disease.
    Gut. 2021 Mar 15. pii: gutjnl-2021-324214. doi: 10.1136/gutjnl-2021-324214.
    PubMed    


  134. JUZNIC L, Peuker K, Strigli A, Brosch M, et al
    SETDB1 is required for intestinal epithelial differentiation and the prevention of intestinal inflammation.
    Gut. 2021;70:485-498.
    PubMed     Abstract available


    February 2021
  135. HU S, Vich Vila A, Gacesa R, Collij V, et al
    Whole exome sequencing analyses reveal gene-microbiota interactions in the context of IBD.
    Gut. 2021;70:285-296.
    PubMed     Abstract available


  136. TAKENAKA K, Kimura M, Ohtsuka K
    Colonic strictures mimicking Crohn's disease.
    Gut. 2021;70:233-387.
    PubMed    


    January 2021
  137. D'HAENS GR, van Deventer S
    25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future.
    Gut. 2021 Jan 11. pii: gutjnl-2019-320022. doi: 10.1136/gutjnl-2019-320022.
    PubMed     Abstract available


    December 2020
  138. LU TX, Dapas M, Lin E, Peters T, et al
    The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies.
    Gut. 2020 Dec 17. pii: gutjnl-2020-321609. doi: 10.1136/gutjnl-2020-321609.
    PubMed     Abstract available


  139. HE X, Gao J, Peng L, Hu T, et al
    Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice.
    Gut. 2020 Dec 12. pii: gutjnl-2020-322468. doi: 10.1136/gutjnl-2020-322468.
    PubMed     Abstract available


  140. HAIFER C, Saikal A, Paramsothy R, Kaakoush NO, et al
    Response to faecal microbiota transplantation in ulcerative colitis is not sustained long term following induction therapy.
    Gut. 2020 Dec 10. pii: gutjnl-2020-323581. doi: 10.1136/gutjnl-2020-323581.
    PubMed    


  141. PAONE P, Cani PD
    Mucus barrier, mucins and gut microbiota: the expected slimy partners?
    Gut. 2020;69:2232-2243.
    PubMed     Abstract available


    November 2020
  142. DERKINDEREN P, Noble W, Neunlist M, Rolli-Derkinderen M, et al
    Upregulation of enteric alpha-synuclein as a possible link between inflammatory bowel disease and Parkinson's disease.
    Gut. 2020 Nov 17. pii: gutjnl-2020-323482. doi: 10.1136/gutjnl-2020-323482.
    PubMed    


  143. KHALOIAN S, Rath E, Hammoudi N, Gleisinger E, et al
    Mitochondrial impairment drives intestinal stem cell transition into dysfunctional Paneth cells predicting Crohn's disease recurrence.
    Gut. 2020;69:1939-1951.
    PubMed     Abstract available


    October 2020
  144. BLACKWELL J, Saxena S, Petersen I, Hotopf M, et al
    Depression in individuals who subsequently develop inflammatory bowel disease: a population-based nested case-control study.
    Gut. 2020 Oct 27. pii: gutjnl-2020-322308. doi: 10.1136/gutjnl-2020-322308.
    PubMed     Abstract available


  145. LEE HS, Lobbestael E, Vermeire S, Sabino J, et al
    Inflammatory bowel disease and Parkinson's disease: common pathophysiological links.
    Gut. 2020 Oct 16. pii: gutjnl-2020-322429. doi: 10.1136/gutjnl-2020-322429.
    PubMed     Abstract available


  146. KANIS SL, Modderman S, Escher JC, Erler N, et al
    Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
    Gut. 2020 Oct 12. pii: gutjnl-2019-319129. doi: 10.1136/gutjnl-2019-319129.
    PubMed     Abstract available


  147. ASCHENBRENNER D, Quaranta M, Banerjee S, Ilott N, et al
    Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance.
    Gut. 2020 Oct 9. pii: gutjnl-2020-321731. doi: 10.1136/gutjnl-2020-321731.
    PubMed     Abstract available


  148. STOURNARAS E, Qian W, Pappas A, Hong YY, et al
    Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.
    Gut. 2020 Oct 1. pii: gutjnl-2019-320185. doi: 10.1136/gutjnl-2019-320185.
    PubMed     Abstract available


  149. JIJON H, Ueno A, Sharifi N, Leung Y, et al
    Elevated interferon-gamma levels during pregnancy are associated with adverse maternofetal outcomes in IBD.
    Gut. 2020;69:1895-1897.
    PubMed    


    September 2020
  150. BEELEN EMJ, van der Woude CJ, de Vries AC
    Intestinal resection rates in Crohn's disease decline across two different epidemiological areas: a consistent observation not merely due to introduction of anti-TNFalpha.
    Gut. 2020;69:1.
    PubMed    


  151. KHALILI H, Hakansson N, Chan SS, Chen Y, et al
    Adherence to a Mediterranean diet is associated with a lower risk of later-onset Crohn's disease: results from two large prospective cohort studies.
    Gut. 2020;69:1637-1644.
    PubMed     Abstract available


    August 2020
  152. SEYED TABIB NS, Madgwick M, Sudhakar P, Verstockt B, et al
    Big data in IBD: big progress for clinical practice.
    Gut. 2020;69:1520-1532.
    PubMed     Abstract available


    July 2020
  153. PAPAMICHAEL K, Cheifetz AS, Irving PM
    New role for azathioprine in case of switching anti-TNFs in IBD.
    Gut. 2020;69:1165-1167.
    PubMed    


  154. ZUO T, Ng SC
    Authors response: giant oversights in the human gut virome.
    Gut. 2020;69:1358.
    PubMed    


  155. SUTTON TDS, Clooney AG, Hill C
    Giant oversights in the human gut virome.
    Gut. 2020;69:1357-1358.
    PubMed    


  156. DANESE S, Schabel E, Ainsworth MA, Peyrin-Biroulet L, et al
    Challenges and opportunities for IBD drug development: from early stage to regulatory approval.
    Gut. 2020;69:1157-1161.
    PubMed    


  157. ROBLIN X, Williet N, Boschetti G, Phelip JM, et al
    Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
    Gut. 2020;69:1206-1212.
    PubMed     Abstract available


    June 2020
  158. KOELINK PJ, Bloemendaal FM, Li B, Westera L, et al
    Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling.
    Gut. 2020;69:1053-1063.
    PubMed     Abstract available


    May 2020
  159. QI X, Liu Y, Wang J, Fallowfield J, et al
    Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.
    Gut. 2020 May 20. pii: gutjnl-2020-321666. doi: 10.1136/gutjnl-2020-321666.
    PubMed    


  160. CLOUGH JN, Omer OS, Tasker S, Lord GM, et al
    Regulatory T-cell therapy in Crohn's disease: challenges and advances.
    Gut. 2020;69:942-952.
    PubMed     Abstract available


  161. KIRCHGESNER J, Nyboe Andersen N, Carrat F, Jess T, et al
    Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study.
    Gut. 2020;69:852-858.
    PubMed     Abstract available


  162. GARG M, Royce SG, Tikellis C, Shallue C, et al
    Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?
    Gut. 2020;69:841-851.
    PubMed     Abstract available


    April 2020
  163. PANACCIONE R, Colombel JF, Travis SPL, Bossuyt P, et al
    Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.
    Gut. 2020;69:658-664.
    PubMed     Abstract available


  164. BOSSUYT P, Vermeire S, Bisschops R
    Scoring endoscopic disease activity in IBD: artificial intelligence sees more and better than we do.
    Gut. 2020;69:788-789.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.